Stereoisomeric compounds and methods for the treatment of gastrointestinal and central nervous system disorders
View Patent ↗The subject invention provides stereoisomeric compounds of formula (X): wherein the variables are as defined herein, and compositions for the safe and effective treatment of various gastrointestinal disorders including, but not limited to, gastroparesis, gastroesophageal reflux and related conditions. The compounds of the subject invention are also useful in treating a variety of conditions involving the central nervous system.
1. A method of treating a gastrointestinal disorder responsive to a 5HT 4 receptor agonist comprising administering to a patient in need of such treatment a therapeutically effective amount of a composition comprising a compound of the formula:
and pharmaceutically acceptable salts thereof.
2. The method according to claim 1 , wherein the compound is a dihydrochloride salt form.
3. The method according to claim 1 , wherein the compound is present in at least about 90% stereoisomeric excess.
4. The method according to claim 1 , wherein the composition comprises a pharmaceutically acceptable excipient, adjuvant, carrier, or solvent.
5. The method according to claim 1 , wherein the composition is administered intravenously.
6. The method according to claim 1 , wherein the composition is administered orally.
7. The method according to claim 1 , wherein the patient is a newborn.
8. A method of treating a gastrointestinal disorder selected from the group consisting of gastroesophageal reflux disease (GERD), emesis, dyspepsia, gastroparesis, constipation, intestinal pseudo-obstruction, and post-operative ileus comprising administering to a patient in need of such treatment a therapeutically effective amount of a compound of the formula
and pharmaceutically acceptable salts thereof.
9. The method according to claim 8 , wherein the compound is a dihydrochloride salt form.
10. The method according to claim 8 , wherein the compound is present in at least about 90% stereoisomeric excess.
11. The method according to claim 8 , wherein the composition comprises a pharmaceutically acceptable excipient, adjuvant, carrier, or solvent.
12. The method according to claim 8 , wherein the composition is administered intravenously.
13. The method according to claim 8 , wherein the composition is administered orally.
14. The method according to claim 8 , wherein the patient is a newborn.
15. A method according to claim 8 , wherein the gastrointestinal disorder is gastroparesis.
16. A method according to claim 7 , wherein the gastrointestinal disorder is constipation.
17. A method according to claim 7 , wherein the gastrointestinal disorder is neonatal gastroesophageal reflux.